• Publications
  • Influence
Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection
TLDR
No clinically significant pharmacokinetic interactions occurred between abacavir, ZDV, and 3TC in HIV-1-infected adults and these agents were generally well tolerated and did not produce unexpected adverse events.
Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers
TLDR
Steady‐state pharmacokinetic parameters of emtricitabine and tenofovir (as ten ofovir disoproxil fumarate) in combination were essentially equivalent versus each drug alone, providing a pharmacokinetics rationale for combining these products in emticitabines/tenofovirs disoposition fumarine fixed‐dose tablets.
Pharmacokinetics of [14C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study
TLDR
The main route of elimination for oral abacavir in humans is metabolism, with <2% of a dose recovered in urine as unchanged drug.
Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults
TLDR
Amprenavir is an HIV protease inhibitor with favorable absorption and clearance pharmacokinetics that is only minimally affected by administration with food and appears to be safe and well tolerated over the dose range of 150 to 1200 mg.
The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
TLDR
The data suggest that zolmitriptan undergoes first-pass metabolism and this is more extensive in men than in women, and there are no significant unidentified metabolites in man.
Pharmacokinetics of Tenofovir Disoproxil Fumarate and Ritonavir-Boosted Saquinavir Mesylate Administered Alone or in Combination at Steady State
TLDR
No clinically relevant interactions between TDF and RTV-boosted SQV were observed under conditions simulating clinical practice, and modestly increased SQV exposures are not clinically meaningful given its clinical use with RTV already results in >10-fold-higher SQV levels.
Abacavir: Absolute Bioavailability, Bioequivalence of Three Oral Formulations, and Effect of Food
TLDR
This study aims to determine the absolute bioavailability of a single 300‐mg abacavir hemisulfate tablet, as well as the bioequivalence of two oral abacvir formulations.
Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males
TLDR
Amprenavir inhibits the ERMBT, rifampin and rifabutin are equipotent inducers of the ER MBT, and the combination is poorly tolerated.
Long-term Safety and Efficacy of a Once-Daily Regimen of Emtricitabine, Didanosine, and Efavirenz in HIV-Infected, Therapy-Naive Children and Adolescents: Pediatric AIDS Clinical Trials Group
TLDR
A once-daily regimen of emtricitabine, didanosine, and efavirenz proved to be safe and tolerable and demonstrated good immunologic and virologic efficacy in this 2-year study.
Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial.
TLDR
This randomized placebo-controlled phase II trial evaluated pre-emptive treatment with BCV for the prevention of adenovirus disease in pediatric and adult allogeneic HCT recipients with asymptomatic adenavirus viremia to confirm the antiviral activity of BCV against adenOViruses.
...
1
2
3
4
...